'My personal view is that companies controlling that information is not the ideal,' Robert Califf tells BIO. 'That doesn’t mean I’ll carry the day.'
SAN FRANCISCO – FDA Commissioner Robert Califf offered some discouraging words about more permissive regulations for off-label promotion during a talk at the Biotechnology Innovation Organization's International Convention on June 7.
Citing the ethical obligations of clinical research and his own impressions of industry behavior, Califf argued that information about medical products should continue to stem primarily from approved
Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.
President Trump's ongoing interest in the policy, which would ensure the US government pays no more for prescription drugs than the lowest price available in comparable countries, continues to gain attention.
HHS Secretary Robert F. Kennedy Jr. regularly decries the “conflicts of interest” he believes abound in advisory committees, but his concerns, as well as a recent “policy directive” eliminating industry representatives, seem driven by a misunderstanding of the panels’ jobs.
